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Wearable artificial 
kidneys?
The replacement of organ function 
by a mechanical device has long been 
the dream of biomedical engineers. 
Its development usually starts with 
a clunky prototype and continues as 
small incremental changes are made 
to reduce the size and increase power 
until a wearable, unobtrusive—even 
invisible—machine is achieved. This 
happened with the artificial pacemaker. 
In the case of developing an artificial 
kidney, the challenges are more diffi-
cult than those for the heart, given that 
the kidney needs to ‘purify’ the blood. 
Hence, the machine must have access to 
high blood flow. In this issue, Gura et 
al. present the development of a light-
weight, wearable, continuous ambula-
tory ultrafiltration device. It achieves 
a blood flow of more than 100 ml/min 
and produces an ultrafiltrate of approx-
imately 100 ml/h. It is a long way from 
an implantable defibrillator, but long 
journeys have to start somewhere. See 
page 497.
Pathway of tubular 
injury by cisplatin
Cisplatin, a commonly used chemother-
apeutic agent, has well-known renal tox-
icities. Its use in experimental animals 
has been a fruitful area of research, and 
Kuwana et al. present new research 
regarding the pathway involved during 
cisplatin nephrotoxicity. The authors 
found that mice lacking phospho-
inositide-3 kinase (PI3K), when treated 
with a conventional dose of cisplatin, 
were more susceptible to death than 
their wild-type controls. They found that 
PI3K signaled to another kinase, Akt, 
and that phosphorylation of Akt in renal 
tubules was prevented in the knockout 
mice. The knockout animals had poorer 
renal function and more apoptotic cells 
in their tubules. When tubular cells from 
these knockout animals were cultured in 
vitro, they were also more susceptible to 
cisplatin and developed apoptosis. But 
the cell death pathway was ameliorated 
by transfection of a dominant active 
form of PI3K. These results suggest 
that the PI3K-γ–Akt pathway is a renal-
protective mechanism when cells are 
exposed to toxins. See page 430.
Uric acid and kidney 
stones
A number of early studies suggest that 
uric acid excretion plays a signiﬁcant 
role in the production of calcium oxalate 
stones. Some of these studies were epi-
demiological, but others were based on 
physical chemistry of uric acid crystals 
and the similarity of their surfaces to 
those of calcium oxalate crystals. Fur-
ther treatment with allopurinol has been 
found to reduce the incidence of neph-
rolithiasis among stone formers. Curhan 
and Taylor performed a cross-sectional 
study of 24-hour urine excretion and the 
risk of kidney stone formation in a large 
cohort of patients, two-thirds of whom 
had stone disease. They found a variety 
of results. In men, urinary uric acid lev-
els were inversely correlated with stone 
disease, whereas in older women, no 
correlation was found, and, in younger 
women, an insigniﬁcant correlation was 
found. The correlations identiﬁed in the 
present study are far greater than those 
of previous studies. While the primary 
event in calcium oxalate nephrolithiasis 
is the level of calcium and oxalate in the 
urine, other factors may play a secondary 
role. See page 489.
